The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
Ecolab Inc., a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and resources vital...
The Waters™ Alliance™ iS High Performance Liquid Chromatography (HPLC) System brings a new level of simplicity and instrument intelligence to...
In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupi...
Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases (CMDs...
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to...
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to ...
The Problem with EzriCare EyedropsWhen you use eyedrops or any other eye product, you trust the product to help, and not hurt, your eye health. But the pri...
Ideal for the transportation of life-saving pharmaceutical, biotech and life-science products, Tower’s robust, reliable, reusable solutions are a wel...
Oligonucleotide therapeutics have unlocked new treatment possibilities for rare and fatal diseases often associated with undruggable proteins.1 Here, ...
The Pipette Manager serves as a wireless control panel for Eppendorf's connected electronic pipettes, adding new features and revolutionizing the speed and...
Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections...
CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be eva...
© 2025 Biopharma Boardroom. All Rights Reserved.
